188 related articles for article (PubMed ID: 21352267)
1. Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.
Malhotra B; Darsey E; Crownover P; Fang J; Glue P
Br J Clin Pharmacol; 2011 Aug; 72(2):226-34. PubMed ID: 21352267
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine.
Simon HU; Malhotra B
Swiss Med Wkly; 2009 Mar; 139(9-10):146-51. PubMed ID: 19145494
[TBL] [Abstract][Full Text] [Related]
3. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine.
Malhotra B; Gandelman K; Sachse R; Wood N; Michel MC
Curr Med Chem; 2009; 16(33):4481-9. PubMed ID: 19835561
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic profile of fesoterodine.
Malhotra B; Guan Z; Wood N; Gandelman K
Int J Clin Pharmacol Ther; 2008 Nov; 46(11):556-63. PubMed ID: 19000553
[TBL] [Abstract][Full Text] [Related]
5. Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine.
Olsson B; Szamosi J
Clin Pharmacokinet; 2001; 40(3):227-35. PubMed ID: 11327200
[TBL] [Abstract][Full Text] [Related]
6. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine.
Brynne N; Dalén P; Alván G; Bertilsson L; Gabrielsson J
Clin Pharmacol Ther; 1998 May; 63(5):529-39. PubMed ID: 9630826
[TBL] [Abstract][Full Text] [Related]
7. Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance.
Brynne N; Svanström C; Aberg-Wistedt A; Hallén B; Bertilsson L
Br J Clin Pharmacol; 1999 Oct; 48(4):553-63. PubMed ID: 10583026
[TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing.
Malhotra BK; Crownover PH; LaBadie R; Glue P; MacDiarmid SA
Eur J Clin Pharmacol; 2010 Feb; 66(2):171-6. PubMed ID: 19915829
[TBL] [Abstract][Full Text] [Related]
9. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron.
Lin J; Goosen TC; Tse S; Yamagami H; Malhotra B
J Clin Pharmacol; 2019 Nov; 59(11):1505-1518. PubMed ID: 31090092
[TBL] [Abstract][Full Text] [Related]
10. Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics.
Oishi M; Chiba K; Malhotra B; Suwa T
Drug Metab Dispos; 2010 Sep; 38(9):1456-63. PubMed ID: 20530222
[TBL] [Abstract][Full Text] [Related]
11. Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects.
Malhotra B; Dickins M; Alvey C; Jumadilova Z; Li X; Duczynski G; Gandelman K
Br J Clin Pharmacol; 2011 Aug; 72(2):263-9. PubMed ID: 21545485
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of drug-drug interactions with fesoterodine.
Malhotra B; Sachse R; Wood N
Eur J Clin Pharmacol; 2009 Jun; 65(6):551-60. PubMed ID: 19347334
[TBL] [Abstract][Full Text] [Related]
13. Food increases the bioavailability of tolterodine but not effective exposure.
Olsson B; Brynne N; Johansson C; Arnberg H
J Clin Pharmacol; 2001 Mar; 41(3):298-304. PubMed ID: 11269570
[TBL] [Abstract][Full Text] [Related]
14. Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder.
Olsson B; Szamosi J
Clin Pharmacokinet; 2001; 40(2):135-43. PubMed ID: 11286323
[TBL] [Abstract][Full Text] [Related]
15. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.
Brynne N; Forslund C; Hallén B; Gustafsson LL; Bertilsson L
Br J Clin Pharmacol; 1999 Oct; 48(4):564-72. PubMed ID: 10583027
[TBL] [Abstract][Full Text] [Related]
16. Effect of tolterodine on sleep structure modulated by CYP2D6 genotype.
Diefenbach K; Jaeger K; Wollny A; Penzel T; Fietze I; Roots I
Sleep Med; 2008 Jul; 9(5):579-82. PubMed ID: 17921051
[TBL] [Abstract][Full Text] [Related]
17. Influence of food on the pharmacokinetic profile of fesoterodine.
Malhotra B; Sachse R; Wood N
Int J Clin Pharmacol Ther; 2009 Jun; 47(6):384-90. PubMed ID: 19473600
[TBL] [Abstract][Full Text] [Related]
18. Multiple-dose pharmacokinetics of fesoterodine sustained-release in healthy Korean volunteers.
Shin D; Shin KH; Lee S; Lim KS; Cho JY; Jang IJ; Shin SG; Yu KS
Int J Clin Pharmacol Ther; 2012 Oct; 50(10):722-8. PubMed ID: 22853865
[TBL] [Abstract][Full Text] [Related]
19. Influence of CYP2D6 genetic polymorphism on pharmacokinetics of active moiety of tolterodine.
Byeon JY; Lee CM; Lee YJ; Kim YH; Kim SH; Jung EH; Chae WK; Lee YJ; Jang CG; Lee SY
Arch Pharm Res; 2019 Feb; 42(2):182-190. PubMed ID: 30542809
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of the 5-hydroxymethyl metabolite of tolterodine after administration of fesoterodine sustained release tablet in Western and East Asian populations.
Oishi M; Tomono Y; Yamagami H; Malhotra B
J Clin Pharmacol; 2014 Aug; 54(8):928-36. PubMed ID: 24619889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
